---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-002343"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T15:50:21.055889+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Oramed Phase 3 oral insulin trial fails; discontinues T2D program

## Summary
- Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.
- Secondary endpoint (fasting plasma glucose) also missed; no serious drug-related adverse events.
- Company will discontinue all oral insulin clinical activities for type 2 diabetes.

## SEC filing metadata
- accession: 0001213900-23-002343
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/0001213900-23-002343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/ea171576-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-002343
- JSON: https://secwatch.observer/filing/0001213900-23-002343.json
- Plain text: https://secwatch.observer/filing/0001213900-23-002343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.